Sequoia Financial Advisors LLC Has $2.24 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Sequoia Financial Advisors LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,947 shares of the biopharmaceutical company’s stock after buying an additional 1,198 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Gilead Sciences were worth $2,239,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GILD. TRUE Private Wealth Advisors bought a new stake in Gilead Sciences in the 4th quarter valued at $25,000. Pin Oak Investment Advisors Inc. bought a new stake in Gilead Sciences in the 4th quarter valued at $26,000. Baldwin Brothers Inc. MA increased its holdings in Gilead Sciences by 63.3% in the 1st quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 136 shares during the period. IndexIQ Advisors LLC bought a new stake in Gilead Sciences in the 4th quarter valued at $28,000. Finally, TFO TDC LLC bought a new stake in Gilead Sciences in the 4th quarter valued at $29,000. 77.34% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have recently weighed in on the stock. Morgan Stanley upped their target price on shares of Gilead Sciences from $75.00 to $77.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Sanford C. Bernstein lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $78.00 to $70.00 in a report on Thursday, February 6th. Cantor Fitzgerald upped their target price on shares of Gilead Sciences from $78.00 to $86.00 and gave the stock an “overweight” rating in a report on Tuesday, April 7th. SunTrust Banks lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating and set a $70.00 target price on the stock. in a report on Friday, May 1st. Finally, Credit Suisse Group reaffirmed a “sell” rating and issued a $60.00 target price on shares of Gilead Sciences in a report on Friday, April 17th. Seven equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $78.15.

Gilead Sciences stock traded down $0.16 during trading hours on Friday, reaching $73.34. 6,157,451 shares of the company’s stock traded hands, compared to its average volume of 19,139,120. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04. Gilead Sciences, Inc. has a fifty-two week low of $60.89 and a fifty-two week high of $85.97. The firm has a market capitalization of $92.20 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 3.14 and a beta of 0.72. The firm’s 50 day moving average is $77.78 and its 200-day moving average is $70.16.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.11. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.44 billion. During the same period in the prior year, the company posted $1.67 EPS. The company’s revenue was up 5.1% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post 6.34 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Friday, June 12th will be given a dividend of $0.68 per share. The ex-dividend date of this dividend is Thursday, June 11th. This represents a $2.72 dividend on an annualized basis and a yield of 3.71%. Gilead Sciences’s payout ratio is presently 44.30%.

In related news, EVP Brett A. Pletcher sold 13,210 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total value of $1,046,628.30. Following the sale, the executive vice president now directly owns 27,204 shares in the company, valued at approximately $2,155,372.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 10,441 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $70.88, for a total transaction of $740,058.08. Following the completion of the sale, the executive vice president now owns 25,085 shares in the company, valued at $1,778,024.80. The disclosure for this sale can be found here. Insiders sold a total of 60,585 shares of company stock worth $4,671,283 over the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: Cost of Debt

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.